The DOI matches its Crossref record; 82 of the 83 references it cites were found in a registry or an index.
Current and future treatments for Alzheimer's disease
Open accessAbstract
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important medical and social problems in older people in industrialized and non-industrialized nations. To date, only symptomatic treatments exist for this disease, all trying to counterbalance the neurotransmitter disturbance. Three cholinesterase inhibitors (CIs) are currently available and have been approved for the treatment of mild to moderate AD. A further therapeutic option available for moderate to severe AD is memantine, an N-methyl-D-aspartate receptor noncompetitive antagonist. Treatments capable of stopping or at least effectively modifying the course of AD, referred to as 'disease-modifying' drugs, are still under extensive research. To block the progression of the disease they have to interfere with the pathogenic steps responsible for the clinical symptoms, including the deposition of extracellular amyloid β plaques and intracellular neurofibrillary tangle formation, inflammation, oxidative damage, iron deregulation and cholesterol metabolism. In this review we discuss current symptomatic treatments and new potential disease-modifying therapies for AD that are currently being studied in phase I-III trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“After the sequential breakdown of the big precursor protein amyloid precursor protein (APP) by the β- and γ-e -secretase, Aβ peptides with A38, A40, and A42 being the most prevalent forms are generated (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is known to be a non-competitive NMDA receptor antagonist that counteracts the negative effects of high glutamate concentrations in the brain (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“The most efficient and prospective class is passive Ab immunotherapy using mAbs. The chief disadvantages of this class of medicines are cerebral microhemorrhages and vasogenic edema (Yiannopoulou et al., 2013).”
From An update on the novel and approved drugs for Alzheimer disease (2022) · cites this paper as Yiannopoulou et al., 2013
In the citing paper
“Memantine is a noncompetitive low-affinity NMDA-receptor open-channel blocker and affects glutamatergic transmission.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“AChEIs attempt at reducing the breakdown of acetylcholine levels in the brain of the patients with AD by inhibiting the responsible enzyme acetylcholinesterase in the synaptic cleft.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“According to the “amyloid hypothesis” Aβ production in the brain initiates a cascade of events leading to the clinical syndrome of AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The basic pathophysiology and neuropathology of AD that drives the current research suggests that the primary histopathologic lesions of AD are the extracellular amyloid plaques and the intracellular Tau neurofibrillary tangles (NFTs).5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The elements of the cascade include local inflammation, oxidation, excitoxicity (excessive glutamate), and tau hyperphosphorylation.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The acetylocholinesterase inhibitors (AChEIs) which are approved for the treatment of AD are donepezil, galantamine, and rivastigmine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“It is the forming of amyloid oligomers to which neurotoxicity is mainly attributed and initiates the amyloid cascade.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Progressive neuronal destruction leads to shortage and imbalance between various neurotransmitters (eg, acetylcholine, dopamine, serotonin) and to the cognitive deficiencies seen in AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“A further therapeutic agent approved for moderate to severe AD is the low-to-moderate affinity, noncompetitive N-methyl-d-aspartate (NMDA) receptor antagonist memantine.4,5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The APP cleavage by α-secretase leads to nonamyloidogenic pathway, whereas APP cleavage by β-secretase (BACE1) leads to amyloidogenic pathway.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The Aβ derives from a protein overexpressed in AD, APP through sequential proteolysis by β-secretase (BACE1) in the extracellular domain and γ-secretase in the transmembrane region.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Sequential cleavage of APP by BACE1 in the extracellular and γ-secretase in the transmembrane area results in the Aβ production.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“The crucial step in AD pathogenesis is the production of amyloid (Aβ), which forms SPs (insoluble and proteolysis-resistant fibrils).”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 is somewhat aggregation-prone and it is mostly found in the cerebral vasculature as a main component of “cerebral amyloid angiopathy.””
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Oligomers can form Aβ-fibrils that will eventually form amyloid plaques.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Major sites of γ-secretase cleavage usually occur in positions 40 and 42 of Aβ, thus Aβ40 and Aβ42 oligomers are the main products of the sequential APP cleavage, as the amyloidogenic pathway is favored in neurons because of the greater plentifulness of BACE1.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ40 usually constitutes more than 50% of total detected Aβ.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Unluckily, concerning γ-secretase, in addition to APP, this particular enzyme acts on many other substances and cleaves different transmembrane proteins. Notch receptor 1, which is essential for control of normal cell differentiation and communication, is among them.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ42 is the most aggregation-prone form and has the tendency to cluster into oligomers.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Aβ38 is soluble, present in the vasculature of patients with sporadic and familial AD.”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“On the contrary, the nonamyloidogenic processing is more favored in other cells without BACE1 predominance.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Cerebral microhemorrhages and vasogenic edema are the main drawbacks in this group of agents.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
In the citing paper
“Abnormal accumulation or dyshomeostasis of metal ions such as iron, copper, and zinc has been associated with the pathophysiology of AD.5”
From Current and Future Treatments in Alzheimer Disease: An Update (2020) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
The cholinergic hypothesis of geriatric memory dysfunction
Bartus, R. T., Dean, R. L., Beer, B., & Lippa, A. S. (1982) · Science · doi:10.1126/science.7046051 · Cited by 5,545
Global prevalence of dementia: a Delphi consensus study
Ferri, C. P., Prince, M. J., Brayne, C., Brodaty, H., Fratiglioni, L., Ganguli, M., Hall, K. S., Hasegawa, K., Hendrie, H. C., Huang, Y., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67889-0 · Cited by 5,336
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Revising the definition of Alzheimer's disease: a new lexicon
Dubois, B., Feldman, H. H., Jacova, C., Cummings, J. L., DeKosky, S. T., Barberger-Gateau, P., Delacourte, A., Frisoni, G., Fox, N. C., Galasko, D., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70223-4 · Cited by 1,869
Statins and the risk of dementia
Jick, H., Zornberg, G. L., Jick, S. S., Seshadri, S. S., & Drachman, D. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03155-x · Cited by 1,764
Tariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403
Clinical effects of Aβ immunization (AN1792) in patients with AD in an interrupted trial
Gilman, S., Koller, M., Black, R. S., Jenkins, L., Griffith, S. G., Fox, N. C., Eisner, L., Kirby, L., Rovira, M. B., Forette, F., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000159740.16984.3c · Cited by 1,329
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155
Clinical trial of indomethacin in Alzheimer's disease
Rogers, J., Kirby, L., Hempelman, S. R., Berry, D. A., McGeer, P. L., Kaszniak, A. W., Zalinski, J., Cofield, M., Mansukhani, L., Willson, P., et al. (1993) · Neurology · doi:10.1212/wnl.43.8.1609 · Cited by 991
Research works printed but not linked: 6
- Alva G., 2008, Psychiatry (Edgmont), 5, 27
- Ballard C., 2010, CNS Drugs, 24, 729
- Cummings J., 2008, Primary Psychiatry, 15, 66
- Hansen R., 2008, Clin Interv Aging, 3, 211
- Hey J., Koelsch G., Bilcer G., Jacobs A., Tolar M., Tang J. (2008) Single dose administration of the b-secretase inhibitor CTS21166 (ASP1720) reduces plasma Aβ40 in human subjects. Presented by Dr Koelsch in the International Conference on Alzheimer’s Disease (ICAD), Chicago, IL, USA, 26–31 July 2008. Available at: http://www.alzforum.org/new/detail.asp?id=1790
- Yiannopoulou K., 2009, Primary Psychiatry, 16, 29
Cited by
Sorted by citations
Items 301–400 of 682
Carbon Nanostructure-Based Materials: A Novel Tool for Detection of Alzheimer’s Disease
Ashfaq, M., Talreja, N., Chuahan, D., & Srituravanich, W. (2019) · Springer eBooks · doi:10.1007/978-981-13-9636-6_4 · Cited by 16
Suwanhom, P., Nualnoi, T., Khongkow, P., Lee, V. S., & Lomlim, L. (2020) · Medicinal Chemistry Research · doi:10.1007/s00044-020-02508-5 · Cited by 16
Hippocampal Subfield Volumes in Middle-Aged Adults at Risk of Dementia
McKeever, A., Paris, A., Cullen, J., Hayes, L., Ritchie, C., Ritchie, K., Waldman, A., Wells, K., Busza, A., Carrière, I., et al. (2020) · Journal of Alzheimer's Disease · doi:10.3233/jad-200238 · Cited by 15
Huntingtin Levels are Elevated in Hippocampal Post-Mortem Samples of Alzheimer’s Disease Brain
Axenhus, M., Winblad, B. G., Tjernberg, L. O., & Schedin‐Weiss, S. (2020) · Current Alzheimer Research · doi:10.2174/1567205017666201203125622 · Cited by 15
Narasimhan, R., Muthukumaran, G., & McGlade, C. (2021) · International Journal of Alzheimer s Disease · doi:10.1155/2021/2679398 · Cited by 16
Wu, F., Li, W., Lu, H., & Li, L. (2025) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2025.101003 · Cited by 16
Dalvi, T., Dewangan, B., Agarwal, G., Suchita, D. S., Jain, A. K., Srivastava, A., & Sahu, B. (2021) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2021.127999 · Cited by 15
Analysis of Shared Genetic Regulatory Networks for Alzheimer’s Disease and Epilepsy
Wang, X., Liu, S., Lu, H. J., Guan, Y., Wu, H., & Ji, Y. (2021) · BioMed Research International · doi:10.1155/2021/6692974 · Cited by 15
Experimental modelling of Alzheimer's disease for therapeutic screening
Blaikie, L., Kay, G., Maciel, P., & Lin, P. K. T. (2022) · European Journal of Medicinal Chemistry Reports · doi:10.1016/j.ejmcr.2022.100044 · Cited by 16
Diagnosing and Treating Alzheimer Disease During the Early Stage
Burke, A. D., & Goldfarb, D. (2023) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.li21019ah3c · Cited by 16
Iwuchukwu, E. A., Olotu, F. A., Agoni, C., & Soliman, M. E. S. (2019) · Medical Hypotheses · doi:10.1016/j.mehy.2019.109277 · Cited by 15
Oña, G., & Bouso, J. C. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867326666191212103330 · Cited by 18
Computational strategy for visualizing structures and teaching biochemistry
Abreu, P. A., Carvalho, K. D. L., Rabelo, V. W., & Castro, H. C. (2018) · Biochemistry and Molecular Biology Education · doi:10.1002/bmb.21199 · Cited by 15
Crnich, E., Lullo, R., Tabaka, A. L., Havens, M. A., & Kissel, D. S. (2021) · Journal of Inorganic Biochemistry · doi:10.1016/j.jinorgbio.2021.111493 · Cited by 14
Ramakrishnan, P., Joshi, A., Fazil, M., & Yadav, P. (2023) · Life Sciences · doi:10.1016/j.lfs.2023.122334 · Cited by 13
Gene therapy: an alternative to treat Alzheimer’s disease
Doshi, V., Joshi, G., Sharma, S., & Choudhary, D. K. (2023) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-023-02873-z · Cited by 14
Kumar, V., Kumar, B., Dwivedi, A. R., Mehta, D., Kumar, N., Bajaj, B., Arora, T., Prashar, V., Parkash, J., & Kumar, V. (2020) · ChemistrySelect · doi:10.1002/slct.202002425 · Cited by 14
Shasaltaneh, M. D., Naghdi, N., Ramezani, S., Alizadeh, L., & Riazi, G. H. (2021) · Planta Medica · doi:10.1055/a-1502-7083 · Cited by 14
Avram, S., Udrea, A.-M., Nuță, D. C., Limban, C., Balea, A. C., Căproiu, M. T., Dumitraşcu, F., Buiu, C., & TELEHOIU, A. T. B. (2021) · Molecules · doi:10.3390/molecules26144160 · Cited by 14
Pervaiz, A., Jan, M. S., Shah, S. M. H., Khan, A., Zafar, R., Ansari, B., Shahid, M. M., Hussain, F., Khan, M. I., Zeb, A., et al. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2069862 · Cited by 14
Dementia Scale Score Classification Based on Daily Activities Using Multiple Sensors
Minamisawa, A., Okada, S., Inoue, K., & Noguchi, M. (2022) · IEEE Access · doi:10.1109/access.2022.3165208 · Cited by 14
The current state of artificial intelligence-augmented digitized neurocognitive screening test
Sirilertmekasakul, C., Rattanawong, W., Gongvatana, A., & Srikiatkhachorn, A. (2023) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2023.1133632 · Cited by 14
Akgüller, Ö., Balcı, M. A., & Cioca, G. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262010003 · Cited by 13
Anticholinesterase Compounds from Endemic Prangos uechtritzii
Albayrak, G., Demir, S., Koyu, H., & Baykan, Ş. (2022) · Chemistry & Biodiversity · doi:10.1002/cbdv.202200557 · Cited by 15
Dubey, A., Dhas, N. L., Naha, A., Rani, U., V, Ravi, G. S., Shetty, A., Shetty, C. R., & Hebbar, S. (2022) · F1000Research · doi:10.12688/f1000research.128874.1 · Cited by 13
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
Ameen, T. B., Ali, U., Salma, O., Samee, M. A., Abbas, S. M. I., Kashif, S. N., Arifi, M. A., Ali, M., Khowaja, M., Ali, S. M. S., et al. (2025) · The Egyptian Journal of Neurology Psychiatry and Neurosurgery · doi:10.1186/s41983-025-00968-3 · Cited by 20
Promoting supported ambulation in persons with advanced Alzheimer’s disease: a pilot study
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., D’Amico, F., Pinto, K., Vanna, F. D., & Caffò, A. O. (2017) · Disability and Rehabilitation Assistive Technology · doi:10.1080/17483107.2017.1297856 · Cited by 13
Yoon, S. K., Bae, K., Hong, D. H., Kim, S. S., Choi, Y. K., & Lim, H. (2020) · Drug Design Development and Therapy · doi:10.2147/dddt.s244957 · Cited by 13
Biomarker Testing: Piercing the Fog of Alzheimer’s and Related Dementia
Horgan, D., Nobili, F. M., Teunissen, C. E., Grimmer, T., Mitrečić, D., Ris, L., Pirtošek, Z., Bernini, C., Federico, A., Blackburn, D. J., et al. (2020) · Biomedicine Hub · doi:10.1159/000511233 · Cited by 13
Deep Reinforcement Learning-Based Retinal Imaging in Alzheimer’s Disease: Potential and Perspectives
Hui, H. Y. H., Ran, A. R., Dai, J. J., & Cheung, C. Y.-L. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-230055 · Cited by 13
Chen, B., Li, W., Wang, G., Li, G., Liu, J.-Q., Zheng, J., Wang, Q., Li, H., Dai, S., & Huang, J. (2018) · PeerJ · doi:10.7717/peerj.4756 · Cited by 13
New biphenanthrenes with butyrylcholinesterase inhibitory activitiy from Cremastra appendiculata
Liu, L., Yin, Q.-M., Gao, Q., Li, J., Jiang, Y., & Tu, P. (2019) · Natural Product Research · doi:10.1080/14786419.2019.1601091 · Cited by 13
Novel 2-Arylbenzimidazole derivatives as multi-targeting agents to treat Alzheimer’s disease
Tan, O. Ü., Ozadali‐Sari, K., Ayazgök, B., Küçükkılınç, T. T., & Balkan, A. (2017) · Medicinal Chemistry Research · doi:10.1007/s00044-017-1874-1 · Cited by 13
Umar, T., Meena, R., Mustehasan, Kumar, P., & Khan, A. A. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14133 · Cited by 12
Boukhvalova, M. S., Kastrukoff, L. F., & Blanco, J. C. G. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1204852 · Cited by 11
Unsupervised Anomaly Detection of Class Imbalanced Cognition Data Using an Iterative Cleaning Method
Kennedy, R. K. L., Salekshahrezaee, Z., & Khoshgoftaar, T. M. (2023) · IEEE International Conference on Information Reuse and Integration (IRI) · doi:10.1109/iri58017.2023.00060 · Cited by 12
Wang, D., Zheng, J., Sun, X., Xie, L., & Yang, Y. (2023) · Metabolites · doi:10.3390/metabo14010001 · Cited by 12
Jowiseungchungtang Inhibits Amyloid-β Aggregation and Amyloid-β-Mediated Pathology in 5XFAD Mice
Shin, S. J., Jeong, Y.-O., Jeon, S. G., Kim, S., Lee, S.-K., Nam, Y., Park, Y., Kim, D., Lee, Y. S., Choi, H. S., et al. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19124026 · Cited by 12
Study on structural atrophy changes and functional connectivity measures in Alzheimer’s disease
Subramanian, S., Rajamanickam, K., Prakash, J. S., & Ramachandran, M. (2020) · Journal of medical imaging · doi:10.1117/1.jmi.7.1.016002 · Cited by 11
Kandasamy, S., Karthikeyan, S., Sugarthi, S., & Stephen, A. D. (2021) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2021.119856 · Cited by 12
Liu, J., Ha, W., Zhang, H., & Shi, Y. (2022) · Journal of Chromatography A · doi:10.1016/j.chroma.2022.462824 · Cited by 12
Jara-Moreno, D., Castro-Torres, R. D., Ettcheto, M., Auladell, C., Kogan, M. J., Folch, J., Verdaguer, E., Cano, A. C., Busquets, O., Delporte, C. L., et al. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180174 · Cited by 12
Curcumin and Its Nanoformulations as Therapeutic for Alzheimer’s Disease
Kakkar, V., Kumari, P., Adlakha, S., & Kaur, I. P. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_14 · Cited by 12
Saunders, T. S., Gadd, D. A., Spires‐Jones, T. L., King, D., Ritchie, C. W., & Terrera, G. M. (2022) · European Journal of Neuroscience · doi:10.1111/ejn.15656 · Cited by 12
Solana‐Manrique, C., Moltó, M. D., Calap-Quintana, P., Sanz, F., Llorens, J. V., & Paricio, N. (2019) · Springer eBooks · doi:10.1007/978-981-13-2218-1_15 · Cited by 12
Volonté, C., Hu, G., Shaw, C. A., Claudio, V. J., dos Santos, J. A., Vaz, S. H., Sebastião, A. M., Balcar, V. J., Mozley, P. D., Verde, F., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004136 · Cited by 12
Halder, D., Das, S., Jeyaprakash, R. S., & Joseph, A. (2022) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2022.2158136 · Cited by 11
Narasimhan, R., Gopalan, M., Sikkandar, M. Y., Alassaf, A., AlMohimeed, I., Alhussaini, K., Aleid, A., & Sheik, S. B. (2023) · Sensors · doi:10.3390/s23218867 · Cited by 12
Recent Updates on the Development of Therapeutics for the Targeted Treatment of Alzheimer’s Disease
Rajput, S., Malviya, R., Bahadur, S., & Puri, D. (2023) · Current Pharmaceutical Design · doi:10.2174/0113816128274618231105173031 · Cited by 12
Renesteen, E., Boyajian, J. L., Islam, P., Kassab, A., Abosalha, A. K., Makhlouf, S., Santos, M., Chen, H., Shum-Tim, C., & Prakash, S. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115351 · Cited by 11
Gonçalves‐Pereira, R., Pereira, M. P., Serra, S. G., Loesche, A., Csük, R., Silvestre, S., Costa, P. J., Oliveira, M. C., & Xavier, N. M. (2018) · European Journal of Organic Chemistry · doi:10.1002/ejoc.201800245 · Cited by 12
Sasidharakurup, H., & Diwakar, S. (2020) · Applied Network Science · doi:10.1007/s41109-020-00307-w · Cited by 12
Bordone, M. C., & Barbosa‐Morais, N. L. (2020) · Frontiers in Neuroscience · doi:10.3389/fnins.2020.607215 · Cited by 9
Lye, S., Aust, C. E., Griffiths, L. R., & Fernandez, F. (2021) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2021.117332 · Cited by 11
Apelin–13 protects against memory impairment and neuronal loss, Induced by Scopolamine in male rats
Gazmeh, S., Azhir, M., Elyasi, L., Jahanshahi, M., Nikmahzar, E., & Jameie, S. B. (2022) · Metabolic Brain Disease · doi:10.1007/s11011-021-00882-6 · Cited by 11
Denis, P. A. (2013) · Medical Hypotheses · doi:10.1016/j.mehy.2013.09.008 · Cited by 10
Chen, C., Sharma, P. R., Tan, B. Y., Low, C., & Venketasubramanian, N. (2019) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.12.001 · Cited by 11
Access to Benzylic Quaternary Carbons from Aromatic Ketones
Li, Y., Han, J., Luo, H. C., An, Q., Cao, X., & Li, B. (2019) · Organic Letters · doi:10.1021/acs.orglett.9b02204 · Cited by 11
Kandasamy, S., Sivanandam, M., Hunday, G., Pavan, M. S., & Kumaradhas, P. (2019) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2019.07.019 · Cited by 11
Hajjari, S. N., Sadigh‐Eteghad, S., Shanehbandi, D., Teimourian, S., Shahbazi, A., & Mehdizadeh, M. (2021) · Neuroscience · doi:10.1016/j.neuroscience.2021.03.028 · Cited by 11
Koppula, S., Wankhede, N. L., Sammeta, S. S., Shende, P. V., Pawar, R. S., Chimthanawala, N. M. A., Umare, M. D., Taksande, B. G., Upaganlawar, A. B., Umekar, M. J., et al. (2024) · Ageing Research Reviews · doi:10.1016/j.arr.2024.102389 · Cited by 10
Novel disease-modifying therapeutics for the treatment of Alzheimer’s disease
Léger, G. C., & Massoud, F. (2013) · Expert Review of Clinical Pharmacology · doi:10.1586/17512433.2013.811237 · Cited by 10
Modulation of linoleic acid-binding properties of human serum albumin by divalent metal cations
Леонидовна, Н. Е., Permyakov, E. A., Permyakov, S. E., & Андреевна, Л. Е. (2017) · BioMetals · doi:10.1007/s10534-017-0010-5 · Cited by 10
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., D’Amico, F., Pinto, K., & Chiapparino, C. (2017) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317517698793 · Cited by 10
EXPERIMENTAL MODELS OF ALZHEIMER’S DISEASE: ADVANTAGES AND DISADVANTAGES
Iptyshev, A. M., Gorina, Y. V., Lopatina, O. L., Komleva, Y. K., & Salmina, A. B. (2016) · Siberian medical review · doi:10.20333/25000136-2016-4-5-21 · Cited by 10
Cognitive Impairment in Old Age
Nuovo, S. D., Béni, R. D., Borella, E., Marková, H., Laczó, J., & Vyhnálek, M. (2020) · European Psychologist · doi:10.1027/1016-9040/a000391 · Cited by 11
Multi-scale modeling for systematically understanding the key roles of microglia in AD development
Ji, Z., Liu, C., Zhao, W., Soto, C. A., & Zhou, X. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104374 · Cited by 10
Mangia, L. H. R., Ferraz, H. C., de Souza, R. S., Pereira, M. C. D. S., & Pinto, J. C. (2021) · Colloids and Surfaces A Physicochemical and Engineering Aspects · doi:10.1016/j.colsurfa.2021.126776 · Cited by 10
Varinthra, P., Suresh, P., Chokkalingam, P., Ibiayo, A. G., & Liu, I. Y. (2022) · Tzu Chi Medical Journal · doi:10.4103/tcmj.tcmj_139_22 · Cited by 10
Shukla, D., Suryavanshi, A., Bharti, S. K., Asati, V., & Mahapatra, D. K. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266299847240328045737 · Cited by 10
Geniposide and Harpagoside Functionalized Cerium Oxide Nanoparticles as a Potential Neuroprotective
Gutiérrez, R. M. P., Rodríguez–Serrano, L. M., Laguna-Chimal, J., Téllez, M. D. L. L. C., Paredes-Carrera, S. P., & Gómez, J. T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084262 · Cited by 9
Anti-amnesic and Neuroprotective Potential of Genistein Against Alzheimer’s Disease
Singh, N. K., Verma, N. K., Gupta, J. K., & Raghav, J. (2023) · Revista Brasileira de Farmacognosia · doi:10.1007/s43450-023-00452-0 · Cited by 10
Current trends and updates in the treatment of Alzheimer's disease
Parikh, N. H., Parikh, P. K., Rao, H. J., Shah, K., Dave, B. P., & Prajapati, B. G. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00014-5 · Cited by 9
Lan, T. T., Anh, D. T., Pham‐The, H., Dung, D. T. M., Park, E. J., Jang, S. D., Kwon, J. H., Kang, J. S., Thuần, N. T. D., Han, S., et al. (2020) · Chemistry & Biodiversity · doi:10.1002/cbdv.202000290 · Cited by 9
Alexopoulos, P., & Kurz, A. (2015) · Psychopathology · doi:10.1159/000441327 · Cited by 10
Smith, L., & Argentina, V. (2019) · Research in Gerontological Nursing · doi:10.3928/19404921-20190930-04 · Cited by 9
Song, X., Wang, T., Guo, L., Jin, Y., Wang, J., Yin, G., Jiang, K., Wang, L., Huang, H., & Zeng, L. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2804849 · Cited by 8
Sharari, S., Vaikath, N. N., Tsakou, M., Ghanem, S. S., & Vekrellis, K. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411326 · Cited by 9
Shareena, G., & Kumar, D. (2023) · Springer eBooks · doi:10.1007/978-981-99-2657-2_14 · Cited by 8
Beneficial Effects of Spirulina on Brain Health: A Systematic Review
Kumar, S., Saha, S., Singh, K., Singh, T., Miahra, A. K., Dubey, B. N., & Singh, S. (2024) · Current Functional Foods · doi:10.2174/0126668629269256231222092721 · Cited by 17
Akarsu, G. D., & Çetin, A. (2022) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000525617 · Cited by 8
Natural products as a source of cholinesterase inhibitors
de Oliveira, P. C. O., da Silva, G. M., Cass, Q. B., de Moraes, M. C., & Cardoso, C. L. (2024) · Pharmacological Research - Natural Products · doi:10.1016/j.prenap.2024.100099 · Cited by 8
Raheja, S., Girdhar, A., Kamboj, A., Lather, V., & Pandita, D. (2020) · Turkish Journal of Pharmaceutical Sciences · doi:10.4274/tjps.galenos.2020.04379 · Cited by 8
Alqubati, G. M. F., & Algaphari, G. H. (2021) · International Journal of Computer Systems & Software Engineering · doi:10.15282/ijsecs.7.2.2021.4.0087 · Cited by 9
Parween, F., Hossain, M. S., Singh, K. P., & Gupta, T. (2021) · PLoS ONE · doi:10.1371/journal.pone.0258879 · Cited by 8
Dixit, H. (2021) · Bioinformation · doi:10.6026/97320630017798 · Cited by 8
Go, M. J., Kim, J. M., Lee, H. L., Kim, T. Y., Joo, S. G., Kim, J. H., Lee, H. S., Kim, D., & Heo, H. J. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241814084 · Cited by 8
Ranade, D. S., Shravage, B. V., Kumbhar, A. A., Sonavane, U., Jani, V., Joshi, R., & Kulkarni, P. P. (2017) · ChemistrySelect · doi:10.1002/slct.201700588 · Cited by 8
Zhang, H., Zhu, F., Dodge, H. H., Higgins, G. A., Omenn, G. S., Guan, Y., & Initiative, T. A. D. N. (2018) · GigaScience · doi:10.1093/gigascience/giy085 · Cited by 7
Alexandraki, K., Apostolopoulos, N. V., Adamopoulos, C., Stamouli, E., Dalagiorgou, G., Papaioannou, T., Analitis, A., Karamanou, M., Makrilakis, K., Politis, A. M., et al. (2018) · The Journal of Applied Laboratory Medicine · doi:10.1373/jalm.2018.027623 · Cited by 8
Histopathological evaluation of insulin-DMSO formula designed for direct nose-to-brain delivery.
Maher, M. A., Kandeel, W. A., Hammam, O. A., Attia, Y. M., Mahmoud, S. S., & Salah, M. (2022) · PubMed · doi:10.14670/hh-18-421 · Cited by 9
Alzheimer’s Disease: Current and Future Treatments. A Review
Chou, E. (2014) · International Journal of Medical Students · doi:10.5195/ijms.2014.85 · Cited by 8
How Do Retinoids Affect Alzheimer’s Disease and Can They Be Novel Drug Candidates?
Alsharief, M. (2024) · Cureus · doi:10.7759/cureus.57548 · Cited by 8
Short-term administration of iso-α-acids increases transthyretin transcription in the hippocampus
Fukuda, T., Uchida, K., Nakayama, H., & Ano, Y. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.11.066 · Cited by 7
Human CALHM5: Insight in large pore lipid gating ATP channel and associated neurological pathologies
Bhat, E. A., Sajjad, N., Banawas, S. S., & Khan, J. (2021) · Molecular and Cellular Biochemistry · doi:10.1007/s11010-021-04198-y · Cited by 7
Nath, S., Roy, P., Mandal, R., Roy, R., Buell, A. K., Sengupta, N., & Tarafdar, P. K. (2021) · Chemistry - An Asian Journal · doi:10.1002/asia.202100965 · Cited by 7
Kang, M., & Hong, K. (2021) · International Conference on Control, Automation and Systems (ICCAS) · doi:10.23919/iccas52745.2021.9650036 · Cited by 7
Qian, H., Yu, C., Zhu, H., Ding, Q., Cai, Y., Jing, J., Xu, X. P., Guo, R., Zhang, H., Liu, H. S., et al. (2023) · Clinical and Translational Science · doi:10.1111/cts.13490 · Cited by 7
Rahman, M. R., Akter, R., Neelotpol, S., Mayesha, I. I., & Afrose, A. (2023) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/15333175231214974 · Cited by 8
An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies
Deba, F., Peterson, S. L., & Hamouda, A. K. (2019) · Methods in molecular biology · doi:10.1007/978-1-4939-9554-7_23 · Cited by 7
Metadata
- Authors
- Yiannopoulou, K. G., & Papageorgiou, S. G.
- Affiliations
- Laiko General Hospital of Athens (GR)
- National and Kapodistrian University of Athens (GR)
- Venue
- Therapeutic Advances in Neurological Disorders
- Publisher
- SAGE Publications
- Published
- 2012-10-15
- Volume
- 6
- Issue
- 1
- Pages
- 19-33
- ISSN
- 1756-2856 (ISSN-L)
- 1756-2864
- PMC
- PMC3526946
- OpenAlex
- W1987204546
- Cited by
- 677
- References
- 83
- Citations by year
- 2026: 35 · 2025: 55 · 2024: 66 · 2023: 70 · 2022: 84 · 2021: 81 · 2020: 83 · 2019: 61 · 2018: 45 · 2017: 37 · 2016: 27 · 2015: 9 · 2014: 9 · 2013: 14
- FWCI
- 6.86
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Therapeutic Advances in Neurological Disorders (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- Alzheimer's disease, cholinesterase inhibitors, memantine, disease-modifying therapy, symptomatic treatment, amyloid plaques, neurofibrillary tangles, oxidative stress, neuroinflammation, cholesterol metabolism, NMDA receptor antagonists, clinical trials
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
